NAMS
Price
$15.92
Change
-$0.14 (-0.87%)
Updated
Sep 20 closing price
51 days until earnings call
SNDX
Price
$18.27
Change
-$0.36 (-1.93%)
Updated
Sep 20 closing price
46 days until earnings call
Ad is loading...

NAMS vs SNDX

Header iconNAMS vs SNDX Comparison
Open Charts NAMS vs SNDXBanner chart's image
NewAmsterdam Pharma
Price$15.92
Change-$0.14 (-0.87%)
Volume$124.55K
CapitalizationN/A
Syndax Pharmaceuticals
Price$18.27
Change-$0.36 (-1.93%)
Volume$1.23M
CapitalizationN/A
View a ticker or compare two or three
NAMS vs SNDX Comparison Chart
Loading...
NAMS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
NAMS vs. SNDX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a StrongSell and SNDX is a Sell.

COMPARISON
Comparison
Sep 21, 2024
Stock price -- (NAMS: $15.88 vs. SNDX: $18.27)
Brand notoriety: NAMS and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 20% vs. SNDX: 120%
Market capitalization -- NAMS: $1.43B vs. SNDX: $1.55B
NAMS [@Biotechnology] is valued at $1.43B. SNDX’s [@Biotechnology] market capitalization is $1.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $595.57B to $0. The average market capitalization across the [@Biotechnology] industry is $3.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 1 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • NAMS’s FA Score: 1 green, 4 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, SNDX is a better buy in the long-term than NAMS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 4 TA indicator(s) are bullish while SNDX’s TA Score has 4 bullish TA indicator(s).

  • NAMS’s TA Score: 4 bullish, 4 bearish.
  • SNDX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NAMS is a better buy in the short-term than SNDX.

Price Growth

NAMS (@Biotechnology) experienced а -0.50% price change this week, while SNDX (@Biotechnology) price change was -4.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.72%. For the same industry, the average monthly price growth was +1.90%, and the average quarterly price growth was -0.55%.

Reported Earning Dates

NAMS is expected to report earnings on Nov 11, 2024.

SNDX is expected to report earnings on Nov 06, 2024.

Industries' Descriptions

@Biotechnology (+0.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SNDX($1.56B) has a higher market cap than NAMS($1.43B). NAMS YTD gains are higher at: 42.167 vs. SNDX (-15.456). NAMS has higher annual earnings (EBITDA): -205.21M vs. SNDX (-263.84M). SNDX (432M) and NAMS (431M) have equal amount of cash in the bank . NAMS has less debt than SNDX: NAMS (562K) vs SNDX (1.13M). NAMS has higher revenues than SNDX: NAMS (7.42M) vs SNDX (3.5M).
NAMSSNDXNAMS / SNDX
Capitalization1.43B1.56B92%
EBITDA-205.21M-263.84M78%
Gain YTD42.167-15.456-273%
P/E RatioN/AN/A-
Revenue7.42M3.5M212%
Total Cash431M432M100%
Total Debt562K1.13M50%
FUNDAMENTALS RATINGS
SNDX: Fundamental Ratings
SNDX
OUTLOOK RATING
1..100
53
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
PROFIT vs RISK RATING
1..100
52
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
62
P/E GROWTH RATING
1..100
6
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NAMSSNDX
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
47%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
36%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
44%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 26 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
64%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
61%
Bearish Trend 1 day ago
66%
View a ticker or compare two or three
Ad is loading...
NAMS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VCRCX13.730.09
+0.66%
NYLI CBRE Global Infrastructure Class C
HAFRX9.50N/A
N/A
Hartford AARP Balanced Retirement R3
EITMX107.14-0.28
-0.26%
Eaton Vance Tx-Mgd Growth 1.1 I
BRUGX16.84-0.05
-0.30%
MFS Blended Research Value Equity C
TRGOX81.32-0.25
-0.31%
T. Rowe Price Lrg Cp Gr Inv

NAMS and

Correlation & Price change

A.I.dvisor tells us that NAMS and GYRE have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NAMS and GYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
-1.12%
GYRE - NAMS
29%
Poorly correlated
-2.09%
RVMD - NAMS
25%
Poorly correlated
-1.73%
SPRO - NAMS
24%
Poorly correlated
-2.21%
SNDX - NAMS
24%
Poorly correlated
-1.93%
SANA - NAMS
24%
Poorly correlated
-8.12%
More

SNDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNDX has been loosely correlated with RCUS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if SNDX jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNDX
1D Price
Change %
SNDX100%
-1.93%
RCUS - SNDX
50%
Loosely correlated
-1.90%
BPMC - SNDX
48%
Loosely correlated
+0.86%
NTLA - SNDX
46%
Loosely correlated
-4.58%
FOLD - SNDX
46%
Loosely correlated
+2.64%
ARVN - SNDX
46%
Loosely correlated
+0.12%
More